ZUWIFTI
Live / Applied — Second extension granted (statement of use) (as of 23 Oct 2025)
What this means for you
Not registered yet, but its 06 Mar 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98435883
- Mark type
- Stylized text
- Filed
- 06 Mar 2024
- Published for opposition
- 29 Oct 2024
- Attorney of record
- Heather A. McDonald
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
Owner
- Pfizer Inc., New York, NY, US
- Pfizer Inc., New York, NY, US
Prosecution history
- 24 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 Oct 2025 — SOU EXTENSION 2 GRANTED
- 23 Oct 2025 — SOU EXTENSION 2 FILED
- 23 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 03 May 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 02 May 2025 — SOU EXTENSION 1 GRANTED
- 02 May 2025 — SOU EXTENSION 1 FILED
- 02 May 2025 — SOU TEAS EXTENSION RECEIVED
- 10 Dec 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 29 Oct 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 29 Oct 2024 — PUBLISHED FOR OPPOSITION
- 09 Oct 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 19 Sept 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 19 Sept 2024 — ASSIGNED TO EXAMINER
- 17 Jul 2024 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED